Skip to main content
ModernaIn development

Doctors call Moderna, Merck cancer vaccine data a major advancement

Source: Autobound Signal API · 106 signals tracked for Moderna · updated

Get Moderna's live signals in Claude or ChatGPT, or by API

AskWhat changed at Moderna this week? Use Autobound signals for modernatx.com.

What happened

Moderna and Merck released Phase 3 trial data for their personalized cancer vaccine intismeran autogene combined with Keytruda, and are preparing regulatory filings for approval next year.

Source

Article excerpt

In this article Leaked confidential data. A major stock sell-off. Beneath the chaos surrounding Moderna and Merck 's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day. The vaccine, known as intismeran autogene, reduced the risk of melanoma recurrence or death by 42% when given alongside Merck's immunotherapy Keytruda, compared with Keytruda alone. The combination also reduced the risk of cancer spreading to distant parts of the body or death by 38%, compared with just the immunotherapy, according to the trial on roughly 1,100 patients whose tumors were removed by surgery. The stock market's reaction contrasted with the assessment of six melanoma specialists, who told CNBC the results represent a clinically meaningful advance that could eventually become a standard of care for patients who undergo surgery first and have not received immunotherapy before their operation. "This has the potential to be a major breakthrough in melanoma treatment and also cancer immunotherapy in general that will open the door to greater outcomes for patients," said Dr. Sekwon Jang, a melanoma specialist at Inova Schar Cancer and principal investigator at...

Keep reading with a free account

The rest of this article, and every signal for Moderna, is in your free account.

Extracted from this sentence

In an interview ahead of the results, Moderna CEO Stéphane Bancel said the company is finishing a filing with regulators as it aims to get the drug fully approved next year.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
intismeran autogene

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • future tech
  • general technology

Extraction

Confidence
95%
Detected
Oct 23, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7493ed36-58be-0b21-b783-858f0700e370 returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "7493ed36-58be-0b21-b783-858f0700e370",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-23T16:24:56+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/10/23/moderna-merck-cancer-vaccine-data.html",
    "title": "Doctors call Moderna, Merck cancer vaccine data a major advancement - despite Wall Street reaction",
    "excerpt": "In this article Leaked confidential data. A major stock sell-off. Beneath the chaos surrounding Moderna and Merck 's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day. The vaccine, known as intismeran autogene, reduced the risk of melanoma recurrence or death by 42% when given alongside Merck's immunotherapy Keytruda, compared with Keytruda alone. The combination also reduced the risk of cancer spreading to distant parts of the body or death by 38%, compared with just the immunotherapy, according to the trial on roughly 1,100 patients whose tumors were removed by surgery. The stock market's reaction contrasted with the assessment of six melanoma specialists, who told CNBC the results represent a clinically meaningful advance that could eventually become a standard of care for patients who undergo surgery first and have not received immunotherapy before their operation. \"This has the potential to be a major breakthrough in melanoma treatment and also cancer immunotherapy in general that will open the door to greater outcomes for patients,\" said Dr. Sekwon Jang, a melanoma specialist at Inova Schar Cancer and principal investigator at one...",
    "product": "intismeran autogene",
    "summary": "Moderna and Merck released Phase 3 trial data for their personalized cancer vaccine intismeran autogene combined with Keytruda, and are preparing regulatory filings for approval next year.",
    "planning": true,
    "image_url": "https://image.cnbcfm.com/api/v1/image/108250093-17678956902026-01-08t180322z_237136326_rc28ldawa07r_rtrmadp_0_usa-vaccines-hpv.jpeg?v=1767895707&w=1920&h=1080",
    "confidence": 0.95,
    "product_data": {
      "name": "intismeran autogene",
      "full_text": "personalized cancer vaccine, known as intismeran autogene",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "future_tech",
      "general_technology"
    ],
    "published_at": "2026-10-23T16:24:56Z",
    "article_sentence": "In an interview ahead of the results, Moderna CEO Stéphane Bancel said the company is finishing a filing with regulators as it aims to get the drug fully approved next year."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.